1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU
5.1. Introduction
5.2. Type A
5.3. Type B
5.4. Others
6. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. RT-PCR & NAATs
6.2.4. Immunofluorescence Assays
6.2.5. At-Home Flu Testing Kits
6.3. Therapeutics
6.3.1. Antiviral Medications
6.3.2. Vaccines
6.3.3. Others
7. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP
7.1. Introduction
7.2. 0–14 Years
7.3. 15–64 Years
7.4. ≥65 Years
8. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY MODE OF ADMINISTRATION
8.1. Introduction
8.2. Oral
8.3. Intranasal
8.4. Injectable
9. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER
9.1. Introduction
9.2. Hospitals & Hospital Laboratories
9.3. Outpatient Clinic
9.4. Pharmacies & Retail Clinics
9.5. Reference Laboratories
9.6. Home Care/Self-Test Users
10. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. USA
10.2.2. Canada
10.2.3. Mexico
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Others
10.4. Europe
10.4.1. Germany
10.4.2. France
10.4.3. United Kingdom
10.4.4. Spain
10.4.5. Others
10.5. Middle East and Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. Others
10.6. Asia Pacific
10.6.1. China
10.6.2. India
10.6.3. Japan
10.6.4. South Korea
10.6.5. Indonesia
10.6.6. Thailand
10.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. QuidelOrtho Corporation
11.2. F. Hoffmann-La Roche AG
11.3. Becton, Dickinson and Company
11.4. Thermo Fisher Scientific Inc.
11.5. SA Scientific, Ltd.
11.6. Sekisui Diagnostics, LLC
11.7. Meridian Bioscience, Inc.
11.8. Oxford Biosystems Ltd.
11.9. Pfizer Inc.
11.10. Bayer AG
11.11. GlaxoSmithKline plc
11.12. Abbott Laboratories
11.13. Danaher Corporation
11.14. Sanofi S.A.
11.15. Hologic, Inc.
11.16. Luminex Corporation
11.17. DiaSorin S.p.A.
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key Benefits for the Stakeholders
12.5. Research Methodology
12.6. Abbreviations